S65487 (VOB560), a potent and selective BCL-2 inhibitor, is a proagent of S55746. S65487 is also active on BCL-2 mutations, such as G101V and D103Y. S65487 has poor affinity with MCL-1 , BFL-1 and BCL-XL. S65487 induces apoptosis and has anticaner activities. In Vitro S65487 binds to the BH3 hydrophobic groove of BCL-2. S65487 induces apoptosis in a panel of hematological cancer cell lines and inhibits cell proliferation with IC 50 s in the low nM range. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo S65487 induces complete regression in BCL-2-dependent RS4;11 tumors in vivo after a single IV (intravenous) administration. Strong and persistent tumor regression in xenograft models of lymphoid malignancies in mouse and rat are observed at well tolerated doses following weekly IV administration of S65487 in combination with the MCL-1-specific inhibitor, S64315/MIK665 . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid